With the novel vaccine platform BERA, Abera can decorate Outer Membrane Vesicles (OMVs) with large amounts of antigen of one or more varieties. The OMVs enhances the immune response and antigen provides strong and broad protection.
Abera develops a pipeline of vaccine candidates based on its proprietary technology. The lead candidate is a universal pneumococcal vaccine candidate given as a nasal spray now in preparation for clinical trials. Abera also explores applications in personalized immunotherapy.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experience to create innovative vaccines.
Abera is taking Outer Membrane Vesicle technology to the next level by decorating them with high levels of pathogen specific antigens to create efficient vaccine candidates.
Abera combines existing technologies, known antigens and break-through improvements with over 30 years of microbiological experiences into new, innovative vaccines.
Abera Bioscience AB (“Abera” or “the company”) has received a preliminary approval notice for the company’s patent application “Display of heterologous molecules on bacterial cells
Abera Bioscience AB (“Abera” or “the Company”) recruits Ann-Christin Magnusson as the Lab Manager for the newly established lab in Uppsala. Ann-Christin brings extensive experience
Abera Bioscience AB (“Abera” or “the Company”) is taking a significant step in its development and will establish a new laboratory in Uppsala, Sweden, during